Literature DB >> 11092096

Management of spasticity in stroke.

B B Bhakta1.   

Abstract

Spasticity treatment must be considered in relation to other impairments with functional goals defined prior to intervention. The effects of muscle co-contraction and involuntary limb movement associated with exaggerated cutaneous reflexes or effort as well as stretch reflex hyperexcitability need to be considered. Exacerbating factors such as pain must be identified. Physical therapy and conventional orthoses are the mainstays of spasticity management during acute rehabilitation. Botulinum toxin shows promise but needs further evaluation in the context of acute rehabilitation. Phenol chemodenervation can produce good results in spasticity refractory to standard treatments. Muscle strengthening exercises may be appropriate in chronic hemiparesis without adversely affecting tone. Electrical stimulation may be a useful adjunct to other spasticity treatments. Difficulty demonstrating functional benefit from antispasticity treatment may imply that interventions directed at single motor impairments whether weakness or spasticity are not likely to result in functional benefit, but it is their combination that is important.

Entities:  

Mesh:

Year:  2000        PMID: 11092096     DOI: 10.1258/0007142001903111

Source DB:  PubMed          Journal:  Br Med Bull        ISSN: 0007-1420            Impact factor:   4.291


  15 in total

1.  The effect of modified constraint-induced movement therapy on spasticity and motor function of the affected arm in patients with chronic stroke.

Authors:  A Siebers; U Oberg; E Skargren
Journal:  Physiother Can       Date:  2010-10-18       Impact factor: 1.037

2.  Development of the theragnostic optical system for a high-intensity laser therapy (HILT).

Authors:  Sangkwan Lee; Tae-Hoon Kim; Jong-In Youn
Journal:  Lasers Med Sci       Date:  2014-03-15       Impact factor: 3.161

Review 3.  IncobotulinumtoxinA: A Review in Upper Limb Spasticity.

Authors:  Yvette N Lamb; Lesley J Scott
Journal:  Drugs       Date:  2016-09       Impact factor: 9.546

4.  To Evaluate the Effectiveness of TBTS - A Novel Device to do Self-Stretching of Gastroc-Soleus Muscle in Patients with Equinus Deformity.

Authors:  Tufail Muzaffar; Abdul Hamid Rather; Kaleem Ul Haque; Sheikh Javeed Ahmad
Journal:  J Clin Diagn Res       Date:  2017-06-01

5.  Muscle tone changes in the lower limbs of stroke patients induced by trunk stabilization exercises.

Authors:  Min-Hyung Rhee; Laurentius Jongsoon Kim
Journal:  J Phys Ther Sci       Date:  2015-08-21

Review 6.  OnabotulinumtoxinA muscle injection patterns in adult spasticity: a systematic literature review.

Authors:  Luba Nalysnyk; Spyridon Papapetropoulos; Philip Rotella; Jason C Simeone; Katharine E Alter; Alberto Esquenazi
Journal:  BMC Neurol       Date:  2013-09-08       Impact factor: 2.474

7.  Efficacy and safety of transcutaneous electrical acupoint stimulation to treat muscle spasticity following brain injury: a double-blinded, multicenter, randomized controlled trial.

Authors:  Wenli Zhao; Chao Wang; Zhongzheng Li; Lei Chen; Jianbo Li; Weidong Cui; Shasha Ding; Qiang Xi; Fan Wang; Fei Jia; Shuhua Xiao; Yi Guo; Ye Zhao
Journal:  PLoS One       Date:  2015-02-02       Impact factor: 3.240

8.  Technical development of transcutaneous electrical nerve inhibition using medium-frequency alternating current.

Authors:  Yushin Kim; Hang-Jun Cho; Hyung-Soon Park
Journal:  J Neuroeng Rehabil       Date:  2018-08-20       Impact factor: 4.262

9.  Effect of Additional Rehabilitation After Botulinum Toxin-A on Upper Limb Activity in Chronic Stroke: The InTENSE Trial.

Authors:  Natasha A Lannin; Louise Ada; Coralie English; Julie Ratcliffe; Steven G Faux; Mithu Palit; Senen Gonzalez; John Olver; Ian Cameron; Maria Crotty
Journal:  Stroke       Date:  2019-12-09       Impact factor: 7.914

10.  Weakened rate-dependent depression of Hoffmann's reflex and increased motoneuron hyperactivity after motor cortical infarction in mice.

Authors:  S Lee; T Toda; H Kiyama; T Yamashita
Journal:  Cell Death Dis       Date:  2014-01-16       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.